PRCT — PROCEPT BioRobotics Corporation

Summary of PROCEPT BioRobotics Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $83.3 million, a 43% increase year-over-year.
• U.S. Revenue: $73.9 million, up 42% compared to Q3 2024.
• Handpiece and Consumable Revenue: $44.4 million, reflecting a 50% growth year-over-year.
• System Revenue: $24.7 million from U.S. robot placements, a 26% increase year-over-year; 57 new HYDROS systems sold.
• Gross Margin: 64.8%, up 160 basis points year-over-year.
• Net Loss: $21.4 million, slightly higher than the $21 million loss in Q3 2024.
• Adjusted EBITDA: Loss of $7.4 million, improved from a loss of $12.4 million in Q3 2024.
• Cash Position: Approximately $297 million as of September 30, 2025.

2. Strategic Updates and Business Highlights

• Leadership Changes: Larry Wood, newly appointed CEO, emphasized the importance of improving procedure utilization and patient activation.
• Organizational Changes: New Chief Marketing and Strategy Officer, Pooja Sharma, and promotion of Stephen McGill to Senior VP, General Manager, International.
• Focus on Utilization: Initiatives to enhance speed from sale to first procedure and improve overall procedure volume.
• International Growth: Increased investment in international markets to capitalize on opportunities for transformational therapies.
• Clinical Evidence: Continued emphasis on building a robust clinical foundation to support Aquablation therapy, with ongoing studies in prostate cancer.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Expected total revenue of approximately $325.5 million, representing 45% growth compared to 2024.
• System Sales Forecast: Anticipation of selling approximately 213 new robotic systems in the U.S. in 2025, with 65 expected in Q4.
• Handpiece Sales: Projected sales of approximately 52,000 handpieces for the full year, a 61% increase.
• 2026 Revenue Outlook: Anticipated total revenue of $410 million to $430 million, reflecting continued momentum despite expected procedural headwinds in the first half.

4. Bad News, Challenges, or Points of Concern

• Utilization Challenges: Low single-digit growth in utilization for Q3, attributed to delays in the ramp-up of new HYDROS systems.
• Capital Spending Scrutiny: Large hospital systems are increasingly scrutinizing capital expenditures, potentially impacting future sales.
• Inventory Management Issues: Concerns about excess inventory in the field leading to destocking, which may affect handpiece sales in Q4.
• Organizational Transition Risks: Recent leadership changes could create short-term disruptions as the company implements new strategies.

5. Notable Q&A Insights

• Capital Environment: Management expressed confidence in capital sales despite macroeconomic concerns, noting that delays are more about timing than a deteriorating environment.
• Patient Activation Strategy: Larry Wood highlighted the need to educate patients about Aquablation therapy to drive adoption, drawing parallels to his experience with TAVR.
• Direct-to-Consumer Marketing: Discussion on the potential for direct-to-patient advertising to raise awareness, with a focus on cost-effective channels.
• Utilization Focus: Emphasis on improving the transition from system sale to active utilization, with a commitment to enhance the organizational focus on this area.
• Profitability Trajectory: Management reassured that strategic investments will not disrupt the path to profitability, with a focus on long-term growth.

This summary encapsulates the key aspects of PROCEPT BioRobotics' Q3 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced by the company.